paediatrics Brussels 17

NICE Committee Concludes….........

• ‘the dinutuximab regimen appears to confer a small event-free survival advantage and overall survival advantage compared with isotretinoin…’ • ‘2.81 life years (approximately 33.7 months) were gained for the dinutuximab regimen compared with isotretinoin alone’ • i.e. patients could expect to live for nearly 3 years longer if treated with anti-GD2-based immunotherapy rather than retinoic acid maintenance alone. • ‘dinutuximab does not represent a cost-effective use of NHS resources…’